www.swansea.ac.uk

Institute of Life Science Phase Two

Professor Gareth Morgan

Head of School

School of Medicine

Established in 2001, the School of Medicine at Swansea University aims to be a centre of excellence in world-class research and medical education

Principal activities are:

• Education: Four-year Graduate Entry Medicine Programme, BSc Genetics and Medical Genetics Programmes and Higher degree programmes including PhD, MD, MCh and Masters degrees

• Research: Interdisciplinary biomedical and health services research at the Institute of Life Science where 87% of research staff have been recognised as producing research of international quality or above (RAE2008)

• Third Mission: The School of Medicine is also fulfilling its third mission obligations at the Institute of Life Science

Institute of Life Science Phase One

5000m2 Four floors of laboratory space Incubator space is fully occupiedCafe Glas has become a hive of activity

Highlights IBM supercomputer – Blue CBoots Centre for InnovationCalon Cardio-TechnologySeren BioscienceMaimonidex UKAllerna TherapeuticsLondon Women’s Clinic

RAE2008 ResultsGrant income Publication performanceVisits from First and Prime Ministers Visits from Health and Economic Ministers ILS Phase One

Institute of Life Science Phase Two

5000m2 CHIRAL – Health Services Research, Clinical Trials Unit, Health Informatics (HIRU + HIRL)Clinical Research Facility Centre for NanoHealth Research Imaging Business Incubation Innovation and Enterprise

Mass Spectrometry

Facts £28.8m bringing total value of ILS to £80million (over £100m with CNH)£16m Capital build£10m Grant from Department of HealthTripling of business incubation spaceMoving more than 100 people from GroveGround-breaking November 2009 Completion early summer 2011

Proposed view of ILS Phase Two from Swansea University

Abertawe Bro Morgannwg University NHS Trust

ABM University Trust is a key partner in ILS Phase 2. It is involved in the following ways:

• Donation of land worth £1 million to the project

• Integration with current Trust Clinical Research Unit

• Medical imaging

• Health informatics

• Ambulatory Care Centre

Proposed view of ILS Phase Two from Singleton Hospital

Our Obligations

In order for ILS Phase Two to be a success, we need to deliver a range of project outcomes:

• Create 450 high value jobs in three years

• Assist commercial enterprises, 80% of which must be Welsh SMEs

• Populate fifteen units within the incubator space

• Record daily activity on the project including timesheets and enterprise assistance

• Continue to undertake high quality research that advances medical knowledge

Institute of Life Science

Thank you very much to everyone who has been involved in securing ILS Phase Two:

All ILS researchers and client organisationsAll School of Medicine staff

Operational Management GroupILS Executive

Innovation and Enterprise teamCentral University staff

Wales European Funding OfficeWelsh Assembly Government

Departments for Economic Development and Health